Price
Target price
€2.84
€2.84
3.550%
0.1
3.550%
€10.55
26.04.24 / Tradegate
WKN: A3DQSD / Symbol: CLRB / Name: Cellectar BioSciences / Stock / Pharmaceuticals / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cellectar BioSciences Inc. Stock
A very strong showing by Cellectar BioSciences Inc. today, with an increase of €0.10 (3.550%) compared to yesterday's price.
Based on 7 Buy predictions and 9 Sell predictions the sentiment towards Cellectar BioSciences Inc. is rather balanced.
On the other hand, the target price of 10 € is above the current price of 2.84 € for Cellectar BioSciences Inc., so the potential is actually 252.11%.
Pros and Cons of Cellectar BioSciences Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cellectar BioSciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cellectar BioSciences Inc. | 3.550% | -1.389% | -21.547% | 111.940% | 24.561% | -77.097% | - |
| Beximco Pharmaceuticals Ltd. GDR | -0.930% | -5.333% | -2.294% | -5.333% | -3.182% | -55.158% | -23.929% |
| Arca Biopharma | -5.290% | 2.516% | 98.176% | 75.741% | 109.646% | 9.396% | -94.250% |
| SELLAS Life Sciences Group Inc | -5.500% | -5.028% | 38.352% | 10.390% | 39.487% | -80.571% | -99.630% |
Comments
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target raised by analysts at Roth Mkm from $20.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Show more
Ratings data for CLRB provided by MarketBeat
